Jiao Liu, Yabing Zhang, Tingting Ji, Hongxing Li, Bin Mao, Xiaoling Ma
{"title":"Artificial oocyte activation technology as adjuvant therapy for primary ciliary dyskinesia: a report of eight cases and literature review.","authors":"Jiao Liu, Yabing Zhang, Tingting Ji, Hongxing Li, Bin Mao, Xiaoling Ma","doi":"10.1007/s10815-025-03486-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical application effect and feasibility of intracytoplasmic sperm injection (ICSI) combined with artificial oocyte activation (AOA) technology in the treatment of male infertility caused by primary ciliary dyskinesia (PCD).</p><p><strong>Cases report: </strong>Between April 2022 and April 2024, our hospital's reproductive center treated a total of eight patients diagnosed with PCD and concurrent male infertility. Among them, six patients were treated with ICSI in conjunction with AOA as an adjuvant therapy, with their oocytes being subjected to ionomycin treatment for a duration of 15 min post-ICSI. One patient underwent ICSI alone, while another patient chose to use donor sperm. Ultimately, we assessed the fertilization rates and transferable embryo rates of all patients. The statistical results showed that the six patients who received ICSI combined with AOA achieved an average fertilization rate of 77.9% and a transferable embryo rate of 66.7%. Four of these patients achieved clinical pregnancy and live birth after embryo transfer. In contrast, the patient who received only ICSI had a fertilization rate of 51.7% and a transferable embryo rate of 20%.</p><p><strong>Conclusions: </strong>AOA can be used as an adjuvant treatment in ICSI cycles for patients with PCD accompanied by male infertility. It not only increases the fertilization rate but also potentially improves embryo quality, thereby enhancing the transferable embryo rate.</p>","PeriodicalId":15246,"journal":{"name":"Journal of Assisted Reproduction and Genetics","volume":" ","pages":"1885-1893"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Assisted Reproduction and Genetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10815-025-03486-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To explore the clinical application effect and feasibility of intracytoplasmic sperm injection (ICSI) combined with artificial oocyte activation (AOA) technology in the treatment of male infertility caused by primary ciliary dyskinesia (PCD).
Cases report: Between April 2022 and April 2024, our hospital's reproductive center treated a total of eight patients diagnosed with PCD and concurrent male infertility. Among them, six patients were treated with ICSI in conjunction with AOA as an adjuvant therapy, with their oocytes being subjected to ionomycin treatment for a duration of 15 min post-ICSI. One patient underwent ICSI alone, while another patient chose to use donor sperm. Ultimately, we assessed the fertilization rates and transferable embryo rates of all patients. The statistical results showed that the six patients who received ICSI combined with AOA achieved an average fertilization rate of 77.9% and a transferable embryo rate of 66.7%. Four of these patients achieved clinical pregnancy and live birth after embryo transfer. In contrast, the patient who received only ICSI had a fertilization rate of 51.7% and a transferable embryo rate of 20%.
Conclusions: AOA can be used as an adjuvant treatment in ICSI cycles for patients with PCD accompanied by male infertility. It not only increases the fertilization rate but also potentially improves embryo quality, thereby enhancing the transferable embryo rate.
期刊介绍：
The Journal of Assisted Reproduction and Genetics publishes cellular, molecular, genetic, and epigenetic discoveries advancing our understanding of the biology and underlying mechanisms from gametogenesis to offspring health. Special emphasis is placed on the practice and evolution of assisted reproduction technologies (ARTs) with reference to the diagnosis and management of diseases affecting fertility. Our goal is to educate our readership in the translation of basic and clinical discoveries made from human or relevant animal models to the safe and efficacious practice of human ARTs. The scientific rigor and ethical standards embraced by the JARG editorial team ensures a broad international base of expertise guiding the marriage of contemporary clinical research paradigms with basic science discovery. JARG publishes original papers, minireviews, case reports, and opinion pieces often combined into special topic issues that will educate clinicians and scientists with interests in the mechanisms of human development that bear on the treatment of infertility and emerging innovations in human ARTs. The guiding principles of male and female reproductive health impacting pre- and post-conceptional viability and developmental potential are emphasized within the purview of human reproductive health in current and future generations of our species.
The journal is published in cooperation with the American Society for Reproductive Medicine, an organization of more than 8,000 physicians, researchers, nurses, technicians and other professionals dedicated to advancing knowledge and expertise in reproductive biology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
